Skip to main content

Table 2 Candida species and initial empiric antifungal medication received by exposure status

From: Statins in Candidemia: clinical outcomes from a matched cohort study

  Patients on Statins, N (%) Patients Not on Statins, N (%) p-value
Candida Sp.    
Candida albicans 6 (40%) 11 (37%) 0.3
Candida glabrata 4 (27%) 11 (37%) 0.5
Candida parapsilosis 3 (20%) 4 (13%) 0.57
Candida tropicalis 1 (7%) 4 (13%) 0.5
Mixed Candida* 2 (13%) 0 0.2
Antifungal Therapy    
Amphotericin B 1 (7%) 1 (3%) 1.0
echinocandin 7 (47%) 12 (40%) 0.75
fluconazole 7 (47%) 17 (57%) 0.54
  1. * Mixed isolates were 1 C. albicans and C. glabrata, and 1 C. albicans and C. parapsilosis.